Related Experiment Video

Updated: Dec 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Diego Kauffmann-Guerrero1, Rudolf Maria Huber1

  • 1Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany.

Lung Cancer (Auckland, N.Z.)
|March 19, 2020
PubMed

Insights

Small-cell lung cancer (SCLC) treatment options are limited after initial chemotherapy. Lurbinectedin, an RNA-polymerase II inhibitor, shows promise as a new second-line treatment for SCLC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Small-cell lung cancer (SCLC) is a highly malignant subtype of lung cancer.
  • Current second-line treatments for relapsed SCLC have poor efficacy.
  • There is a significant unmet need for improved SCLC therapies.

Purpose of the Study:

  • To review the current data on lurbinectedin for SCLC treatment.
  • To evaluate the impact of lurbinectedin on SCLC patient outcomes.

Main Methods:

  • Review of preclinical and clinical studies on lurbinectedin.
  • Analysis of efficacy and safety data in pretreated SCLC patients.

Main Results:

  • Lurbinectedin demonstrates promising results as a single agent and in combination therapy.
  • The drug has received orphan drug designation from the FDA.
  • Early data suggests potential for improved outcomes in relapsed SCLC.

Conclusions:

  • Lurbinectedin is an emerging therapeutic option for SCLC.
  • Further investigation into lurbinectedin's role in SCLC treatment is warranted.
Keywords:
SCLCchemotherapylurbinectedinorphan drug

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K